Oxford Biomedica plc announced an update on the 18 month supply agreement signed with AstraZeneca UK Ltd. ("AstraZeneca") in September 2020. Following successful manufacture of large-scale batches of AstraZeneca's COVID-19 Vaccine, AstraZeneca has committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021.